Your browser doesn't support javascript.
loading
Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases.
Icard, Charlotte; Mocquot, Pauline; Nogaro, Jean-Claude; Despas, Fabien; Gauthier, Martin.
Afiliación
  • Icard C; Department of Medical and Clinic Pharmacology, 36760CHU de Toulouse, France.
  • Mocquot P; Department of Medical and Clinic Pharmacology, 36760CHU de Toulouse, France.
  • Nogaro JC; Department of Hematology, 54909Institut Universitaire du Cancer-Oncopole, France.
  • Despas F; Department of Medical and Clinic Pharmacology, 36760CHU de Toulouse, France.
  • Gauthier M; UMR1027, Inserm, 173638Université Paul Sabatier, France.
J Oncol Pharm Pract ; 28(2): 453-456, 2022 Mar.
Article en En | MEDLINE | ID: mdl-34590522
INTRODUCTION: Lenalidomide is an immunomodulatory agent with multiple mechanisms of action, and treatment with lenalidomide is associated with adverse events such as thrombosis and abdominal pain; nonetheless, other rarer adverse events do exist, with few knowledge from physicians and pharmacists. For such adverse events, pharmacovigilance databases are of great interest. CASE REPORT: A 71-year-old patient with no rheumatologic history, in complete remission of a mantle-cell lymphoma following rituximab, doxorubicin, vincristine, cyclophosphamide, and prednisone induction, received a maintenance treatment with rituximab and lenalidomide. After each course of lenalidomide and with no other new medication, the patient presented with fever and high inflammatory markers level, and a scapular-belt arthritis. MANAGEMENT AND OUTCOME: The patient was managed with non-steroidal anti-inflammatory drugs and colchicine, with symptomatology and inflammation improvement. After discontinuation of lenalidomide, he had no arthritis relapse; it was then concluded that the patient had a lenalidomide-induced arthritis. We interrogated the national and international (VigiBase®) pharmacovigilance databases and found that arthritis in the context of lenalidomide exposure is a rare finding, with only three reported cases in France; 0.13% of adverse events reported with lenalidomide in the international database VigiBase® were arthritis. DISCUSSION: Our case then reports an uncommon finding, of which both pharmacists and physicians should be aware due to the wide and increasing use of lenalidomide.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis / Farmacovigilancia Límite: Adult / Aged / Humans / Male Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis / Farmacovigilancia Límite: Adult / Aged / Humans / Male Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido